Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Transcriptional repressor which preferentially binds to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may regulate expression of TNF, EGFR and PDGFA. Zusätzlich bieten wir Ihnen Leucine Rich Repeat (In FLII) Interacting Protein 1 Proteine (9) und Leucine Rich Repeat (In FLII) Interacting Protein 1 Kits (5) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 71 products:
Experiments in nude mice demonstrated better response of LRRFIP1 overexpressing glioblastoma multiforme xenografts to teniposide.
regulates a rapid type I interferon (zeige IFNA Antikörper) response
LRRFIP1 and its downstream partner beta-catenin (zeige CTNNB1 Antikörper) constitute another coactivator pathway for IRF3 (zeige IRF3 Antikörper)-mediated production of type I interferon (zeige IFNA Antikörper)
Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) signaling pathway.
High GCF2 (zeige GCFC2 Antikörper) expression is associated with hepatoma.
Higher baseline LRRFIP1 expression in human glioblastoma multiforme tissue (n=60) is associated with better prognosis upon later treatment with teniposide.
Data indicate that LRRFIP1 knockdown increased resting TNF (zeige TNF Antikörper) mRNA level altered the ncRNA abundance at the LRRFIP1 binding region.
The FLI (zeige FLII Antikörper)-interacting domain of LRRFIP1 forms a classic parallel, homodimeric coiled coil with 10 heptad repeats and 22 helical turns.
GCF2/LRRFIP1 plays an important role in colorectal cancer metastasis by regulating RhoA (zeige RHOA Antikörper)-induced cell adhesion.
LRRFIP1 is phosphorylated in response to immunologic stimuli and it is directed to lysosomal structures.
An association study of 6 of the 63 genes in 4235 cases and 6379 controls showed a putative association with myocardial infarction for COMMD7 (COMM domain-containing protein 7 (zeige COMMD7 Antikörper)) and a major deviation from the null hypo thesis for LRRFIP1.
GCF2/LRRFIP1 appears to act as a repressor and occupies the -308 site in cells that do not make TNF-alpha (zeige TNF Antikörper).
Immediately following lipopolysaccharide stimulation, both LRRFIP2 (zeige LRRFIP2 Antikörper) and Flap-1/LRRFIP1 compete with Fliih (zeige FLII Antikörper) for interacting with MyD88 (zeige MYD88 Antikörper) to activate the signaling.
Transcriptional repressor which preferentially binds to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may regulate expression of TNF, EGFR and PDGFA. May control smooth muscle cells proliferation following artery injury through PDGFA repression. May also bind double-stranded RNA. Positively regulates Toll-like receptor (TLR) signaling in response to agonist probably by competing with the negative FLII regulator for MYD88-binding.
leucine rich repeat (in FLII) interacting protein 1
, leucine-rich repeat flightless-interacting protein 1-like
, FLAP (FLI LRR associated protein)
, FLI-LRR-associated protein 1
, H186 FLAP
, LRR FLII-interacting protein 1
, leucine-rich repeat flightless-interacting protein 1
, GC-binding factor 2
, NEDD8-conjugating enzyme
, TAR RNA-interacting protein